COST-EFFECTIVENESS OF TEPOTINIB FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS IN SPAIN

被引：0
|
作者：
Arriola, E. [1 ]
Batteson, R. [2 ]
Hook, E. [2 ]
Wheat, H. [2 ]
Vioix, H. [3 ]
Morros, M. [4 ]
Aguila, M. [4 ]
de los Santos Real, H. [5 ]
Soberon S, Fernandez [5 ]
Brines, M. [5 ]
Vazquez, S. [6 ]
机构：
[1] Hosp Mar, Barcelona, Spain
[2] Delta Hat Ltd, Nottingham, England
[3] Merck KGaA, Healthcare Business, Darmstadt, HE, Germany
[4] Adelphi Targis, Barcelona, Spain
[5] Merck SLU, Madrid, Spain
[6] Hosp Univ Lucus Augusti, Lugo, Spain
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE146
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [11] MOMENT REGISTRY (MET NON SMALL CELL CANCER REGISTRY) FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Thomas, M.
    Christopoulos, P.
    Iams, W. T.
    Mazieres, J.
    Cortot, A. B.
    Peled, N.
    Minuti, G.
    Smit, E. F.
    Ahrens, S.
    Berghoff, K.
    Eggleton, S. P.
    Fries, F.
    Liu, P.
    Mahmoudpour, S. H.
    Menzel, C.
    O'Brate, A.
    Stroh, C.
    Oksen, D.
    VALUE IN HEALTH, 2023, 26 (12) : S527 - S527
  • [12] Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
    Drusbosky, Leylah M.
    Dawar, Richa
    Rodriguez, Estelamari
    Ikpeazu, Chukwuemeka, V
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [13] Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
    Leylah M. Drusbosky
    Richa Dawar
    Estelamari Rodriguez
    Chukwuemeka V. Ikpeazu
    Journal of Hematology & Oncology, 14
  • [14] Non-interventional cohort study on patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping in the US
    Ryder, A.
    Oksen, D.
    Vlahiotis, A.
    Boutmy, E.
    Dietz, L. A.
    Stroh, C.
    Johne, A.
    Walker, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S785 - S785
  • [15] Tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Interim analysis of VISION Cohorts A and C
    Griesinger, Frank
    Thomas, Michael
    Reinmuth, Niels
    Wermke, Martin
    Overbeck, Tobias
    Alt, Juergen
    Henschke, Sven
    Wehler, Thomas
    Ochsenreither, Sebastian
    Garassino, Marina Chiara
    Felip, Enriqueta
    Sakai, Hiroshi
    Bruns, Rolf
    Otto, Gordon
    Johne, Andreas
    Paik, Paul K.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 154 - 154
  • [16] Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer
    Pavlakis, N
    Mitchell, PL
    Slynes, G
    Aristides, M
    Davey, P
    Rajan, N
    Arora, B
    Liepa, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 549S - 549S
  • [17] Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14)
    Furqan, Muhammad
    Karanth, Siddharth
    Goyal, Ravi K.
    Shih, Yu-Hsuan
    Cai, Beilei
    Rombi, Julien
    Davis, Keith L.
    Caro, Nydia
    Saliba, Teddy Rassem
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [18] ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14).
    Yu, Yongfeng
    Ren, Yongxin
    Fang, Jian
    Cao, Lejie
    Liang, Zongan
    Guo, Qisen
    Han, Sen
    Ji, Zimei
    Wang, Ye
    Sun, Yulan
    Chen, Yuan
    Li, Xingya
    Xu, Hua
    Zhou, Jianying
    Jiang, Liyan
    Cheng, Ying
    Han, Zhigang
    Shi, Jianhua
    Chen, Gongyan
    Ma, Rui
    Fan, Yun
    Sun, Sanyuan
    Jiao, Longxian
    Jia, Xiaoyun
    Wang, Linfang
    Lu, Puhan
    Li, Jing
    Xu, Qian
    Luo, Xian
    Su, Weiguo
    Lu, Shun
    CANCER RESEARCH, 2021, 81 (13)
  • [19] Financial impact of tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer bearing METex14 skipping in the United States.
    Stargardter, Matthew
    Yang, Mo
    Tosh, Jon
    Ambavane, Apoorva
    Mittal, Madhav
    Vioix, Helene
    Liu, Frank Xiaoqing
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [20] Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping.
    Le, Xiuning
    Felip, Enriqueta
    Veillon, Remi
    Sakai, Hiroshi
    Cortot, Alexis B.
    Garassino, Marina Chiara
    Mazieres, Julien
    Ramirez, Santiago Viteri
    Senellart, Helene
    Van Meerbeeck, Jan
    Reinmuth, Niels
    Conte, Pier Franco
    Kowalski, Dariusz
    Cho, Byoung Chul
    Straub, Josef
    Scheele, Jurgen
    Juraeva, Dilafruz
    Bruns, Rolf
    Heymach, John
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345